An appraisal of anticancer activity with structure–activity relationship of quinazoline and quinazolinone analogues through EGFR and VEGFR inhibition: A review
Cancer is one of the leading causes of death. Globally a huge number of deaths and new
incidences are reported annually. Heterocyclic compounds have been proved to be very …
incidences are reported annually. Heterocyclic compounds have been proved to be very …
[HTML][HTML] How to make anticancer drugs cross the blood–brain barrier to treat brain metastases
E Angeli, TT Nguyen, A Janin, G Bousquet - International journal of …, 2019 - mdpi.com
The incidence of brain metastases has increased in the last 10 years. However, the survival
of patients with brain metastases remains poor and challenging in daily practice in medical …
of patients with brain metastases remains poor and challenging in daily practice in medical …
Inhibition of brain epidermal growth factor receptor activation: a novel target in neurodegenerative diseases and brain injuries
Several reports have been published recently demonstrating a beneficial effect of epidermal
growth factor receptor (EGFR) inhibitors in improving pathologic and behavioral conditions …
growth factor receptor (EGFR) inhibitors in improving pathologic and behavioral conditions …
[HTML][HTML] Novel 1, 2, 3-triazole erlotinib derivatives as potent IDO1 inhibitors: Design, drug-target interactions prediction, synthesis, biological evaluation, molecular …
GQ Xu, XQ Gong, YY Zhu, XJ Yao, LZ Peng… - Frontiers in …, 2022 - frontiersin.org
Indoleamine 2, 3-dioxygenase 1 (IDO1) plays a predominant role in cancer immunotherapy
which catalyzes the initial and rate limiting steps of the kynurenine pathway as a key …
which catalyzes the initial and rate limiting steps of the kynurenine pathway as a key …
[HTML][HTML] Brain metastasis treatment: the place of tyrosine kinase inhibitors and how to facilitate their diffusion across the blood–brain barrier
E Angeli, G Bousquet - Pharmaceutics, 2021 - mdpi.com
The incidence of brain metastases has been increasing constantly for the last 20 years,
because of better control of metastases outside the brain, and the failure of most drugs to …
because of better control of metastases outside the brain, and the failure of most drugs to …
[HTML][HTML] Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology …
E Carcereny, A Fernández-Nistal, A López, C Montoto… - Oncotarget, 2021 - ncbi.nlm.nih.gov
Abstract Around 3–7% of patients with non-small cell lung cancer (NSCLC), which represent
85% of diagnosed lung cancers, have a rearrangement in the ALK gene that produces an …
85% of diagnosed lung cancers, have a rearrangement in the ALK gene that produces an …
Cytoskeletal Remodeling and Gap Junction Translocation Mediates Blood–Brain Barrier Disruption by Non-invasive Low-Voltage Pulsed Electric Fields
NR Rajagopalan, WR Vista, M Fujimori… - Annals of biomedical …, 2024 - Springer
High-voltage pulsed electric fields (HV-PEF) delivered with invasive needle electrodes for
electroporation applications is known to induce off-target blood–brain barrier (BBB) …
electroporation applications is known to induce off-target blood–brain barrier (BBB) …
[HTML][HTML] Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model
C Masuda, M Sugimoto, D Wakita, M Monnai… - Clinical & Experimental …, 2020 - Springer
Brain metastases are common in patients with non-small-cell lung cancer (NSCLC). The
efficacy of bevacizumab, an anti-vascular endothelial growth factor (VEGF) humanized …
efficacy of bevacizumab, an anti-vascular endothelial growth factor (VEGF) humanized …
Therapeutic approaches for T790M mutation positive non-small-cell lung cancer
I Attili, N Karachaliou, PF Conte… - Expert Review of …, 2018 - Taylor & Francis
Introduction: Epidermal growth factor receptor (EGFR) mutation positive non-small cell lung
cancer (NSCLC) is a subset of lung cancer with demonstrated response to targeted …
cancer (NSCLC) is a subset of lung cancer with demonstrated response to targeted …
[HTML][HTML] A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer
Background ASP8273, a novel, small molecule, irreversible tyrosine kinase inhibitor (TKI)
specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating …
specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating …